GlaxoSmithKline forms an alliance with Regulus for microRNA research

BOSTON GlaxoSmithKline and Regulus Therapeutics LLC announced an alliance to develop and market microRNA-targeted therapeutics, according to published reports.

The Micro-RNA therapeutics would be used to treat inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.

As a result of the deal Regulus, which is a joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, will receive $20 million upfront by GlaxoSmithKline and will be responsible for the discovery and development of the micro-RNA antagonists. GlaxoSmithKline, however, will be able to license the product candidates, according to published reports.